[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
3. Kim SC, Natarajan-Ame S, Lioure B, Chenard MP, Duclos B, Herbrecht R, Bergerat JP: Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol; 2010;2010:812424

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.
  • Background. Localized granulocytic sarcoma of the uterine cervix in the absence of acute myelogenous leukemia (AML) at presentation is very rare, its diagnosis is often delayed, and its prognosis almost always ominous evolving into refractory AML. Case.
  • We present the case of a 30-year-old woman with vaginal bleeding and a large cervical mass.
  • Further evaluation confirmed the presence of a granulocytic sarcoma but failed to reveal systemic involvement.
  • Results. AML type chemotherapy followed by radiotherapy of the uterus led to a durable complete remission.
  • She remains in complete remission six years after diagnosis.
  • Conclusion. Granulocytic sarcoma of the cervix is a rare entity for which early intensive AML type therapy is effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med J. 2006 Oct;36(10):669-71 [16958646.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):493-7 [16019058.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):273-6 [8700651.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):553-7 [15228434.001]
  • [Cites] Br J Radiol. 1989 Nov;62(743):995-8 [2510900.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):483-8 [2732341.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1764-6 [6582998.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Clin Lab Med. 1990 Dec;10(4):889-901 [2272180.001]
  • (PMID = 20454648.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2862322
  •  go-up   go-down


Advertisement
4. Bath LE, Tydeman G, Critchley HO, Anderson RA, Baird DT, Wallace WH: Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing's sarcoma of the pelvis: case report. Hum Reprod; 2004 Nov;19(11):2569-72
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing's sarcoma of the pelvis: case report.
  • We report the case of a 14 year old girl who presented with a non-metastatic Ewing's sarcoma involving her superior pubic ramus.
  • She received 14 courses of alkylating agent-based chemotherapy and direct radiation to her hemi-pelvis (55 Gy) and is alive and disease-free 8 years later.
  • Multiple biopsies of ovarian cortical tissue were cryopreserved, with her written consent, before treatment began.
  • Ovarian failure was confirmed on completion of treatment with cessation of menses and persistently elevated serum gonadotrophin and low estradiol levels on repeated measurement over 2 years.
  • Irregular vaginal bleeding occurred due to radiation vaginitis.
  • Reimplantation of ovarian cortical tissue was considered at 19 years as fertility was desired, but the decision deferred.
  • This is the first case of a spontaneous conception occurring in a young woman with documented ovarian failure in whom ovarian cortical tissue had been cryopreserved.
  • Clinicians should be aware of the possibility of spontaneous conception despite confirmed ovarian failure in young women successfully treated for cancer.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Cryopreservation / methods. Fertilization. Ovary / transplantation. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Infant, Newborn. Male. Menstrual Cycle / physiology. Organ Preservation. Ovarian Diseases / drug therapy. Ovarian Diseases / etiology. Ovulation / drug effects. Ovulation / radiation effects. Pelvis / radiation effects. Pregnancy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15310731.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH: Total pelvic exenteration for primary and recurrent malignancies. World J Surg; 2009 Jul;33(7):1502-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina).
  • METHODS: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma.
  • Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging.
  • Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively.
  • Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%.
  • CONCLUSIONS: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Nov;29(9):743-6 [14602493.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):106-12 [14697427.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):680-3 [14766266.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):972-5 [15498643.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Urol. 1999 Apr;161(4):1057-66 [10081838.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):99-102 [10502433.001]
  • [Cites] Surg Clin North Am. 1950 Oct;30(5):1511-21 [14782163.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):524-8 [15863155.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1257-65 [16912909.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):452-8 [17071043.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):243-8 [16950559.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] J Am Coll Surg. 2000 Jan;190(1):78-83 [10625236.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1546-9 [11775189.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • (PMID = 19421811.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2691931
  •  go-up   go-down


6. Sajdak S, Moszynski R, Opala T: Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII. Eur J Gynaecol Oncol; 2002;23(4):325-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
  • The authors report two cases of successful employment of human recombinant activated factor VII in gynecological oncological patients (endometrial cancer and vaginal sarcoma) without pre-existing coagulopathy.
  • They conclude that recombinant factor VIIa may be an important and effective drug in severe bleeding in gynecological oncology.
  • [MeSH-major] Factor VII Deficiency / drug therapy. Factor VIIa / administration & dosage. Hemostatics / administration & dosage. Uterine Hemorrhage / drug therapy. Uterine Hemorrhage / etiology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / radiotherapy. Administration, Intravaginal. Adult. Aged. Endometrial Neoplasms / complications. Endometrial Neoplasms / radiotherapy. Ethamsylate / administration & dosage. Female. Humans. Infusions, Intravenous. Mandibular Neoplasms / complications. Mandibular Neoplasms / secondary. Mandibular Neoplasms / therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Recombinant Proteins. Sarcoma / complications. Sarcoma / secondary. Sarcoma / therapy. Tranexamic Acid / administration & dosage. Vaginal Neoplasms / complications. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214734.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hemostatics; 0 / Recombinant Proteins; 24YL531VOH / Ethamsylate; 6T84R30KC1 / Tranexamic Acid; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


7. Minig L, Farnetano G, Peiretti M, Roviglione G, Zanagnolo V, Pelosi G, Landoni F: Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review. Ecancermedicalscience; 2008;2:99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review.
  • Synovial sarcomas (SS) account for 5-10% of soft-tissue sarcomas and typically arise in the para-articular regions of adolescents and young adults.
  • Here, we present a first clinical literature report of a patient with an SS arising from the vaginal wall.
  • A 40-year-old patient who presented a necrotic polypoid lesion, measuring 50 mm and extending from the external urethral meatus to the middle part of the anterior vaginal wall.
  • The patient, prior to the radical surgery, received neoadjuvant chemotherapy (ifosfamide and epirubicin) for three cycles.
  • She underwent post-operative external radiotherapy and brachytherapy (50 Gy) due to close margins (<1 mm) in the pathologic specimen.
  • She relapsed 11 and 16 months later with lung metastases, which, both times, were successfully removed by surgical resection.
  • At 24 months from diagnosis, the patient is alive without further evidence of disease.
  • In summary, in the presence of unfavourable prognostic factors, neoadjuvant chemotherapy could be the primary approach to reduce the tumour size and the risk of distant micro-metastases allowing a less aggressive radical surgery if the tumour is located in a non-extremity site.
  • In fact, in our patient we obtained a complete clinical control in the pelvis, avoiding pelvic exenteration with neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275979.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234049
  •  go-up   go-down


8. Skeete DH, Cesar-Rittenberg P, Jong R, Murray SK, Colgan TJ: Myeloid sarcoma of the vagina: a report of 2 cases. J Low Genit Tract Dis; 2010 Apr;14(2):136-41
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma of the vagina: a report of 2 cases.
  • OBJECTIVE: To describe 2 cases of myeloid sarcoma of the vagina, in a patient without a history of acute myeloid leukemia (AML) and in another whose condition was previously diagnosed with AML.
  • MATERIALS AND METHODS: The clinical histories of 2 patients whose conditions were diagnosed with myeloid sarcoma of the vagina were obtained from their medical records.
  • RESULTS: Case 1: A 77-year-old woman with no systemic illnesses presented with a vaginal lump.
  • The histopathologic specimen was evaluated on routine and immunohistochemical stains, and myeloid sarcoma was diagnosed after extensive immunohistochemical analysis.
  • She developed extensive myeloid sarcoma of the skin and AML 4.5 months later; she died 2 weeks later, 5 months after the initial presentation.
  • Physical findings revealed large masses in the vagina and rectovaginal septum, which were confirmed as myeloid sarcoma after biopsy and histologic examination.
  • The patient was treated with pelvic/vaginal radiation.
  • Five months later, she had another leukemic relapse and died within 1 day of palliative chemotherapy.
  • CONCLUSIONS: Myeloid sarcoma of the vagina is extremely rare.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis. Vagina / pathology. Vaginal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354424.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / SAGE protein, human
  •  go-up   go-down


9. Liao Q, Wang J, Han J: [Clinical and pathological analysis on 106 cases with uterine sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2001 Feb;36(2):104-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological analysis on 106 cases with uterine sarcoma].
  • OBJECTIVE: To analyze the clinical features and factors affecting the prognosis of uterine sarcoma with different histological types.
  • METHODS: One hundred and six cases with uterine sarcoma treated were analyzed retrospectively, among which there were 67 cases with leiomyosarcoma (63.2%), 23 with malignant endometrial interstitial sarcomas (21.7%), 16 with malignant Mullerian mixed tumor (15.1%).
  • According to Union Internationale Contre le Cancer (UICC) staging, 70 cases were on stage I, 12 cases were on stage II, 19 cases belonged to stage III, and 5 cases belonged to stage IV. RESULTS:.
  • (1) The patients with leiomyosarcoma and endometrial interstitial sarcoma were relatively younger, the patients of them aged under 50 amounted to 70.1% (47/67) and 60.9% (14/23) respectively, and those aged under 40 amounted to 29.9% (20/67) and 39.1% (9/23) respectively.
  • The patients usually manifested with abnormal vaginal bleeding (67.0%), palpable mass of lower abdomen (32.1%), vaginal discharge (27.4%), pain on lower abdomen (28.4%), symptoms of oppression (25.5%), and discomfort feeling (28.3%). (2) The rate of preoperative diagnosis was 65.9%, especially that of leiomyosarcoma was lowest (42.9%). (3) In treatment, 16.0% of patients was treated by hysterectomy; bilateral salpingo-oophorectomy and pelvic lymphadenectomy; 75.5% of them by hysterectomy and bilateral salpingo-oophorectomy; after operation, 74.5% of them were treated by chemotherapy, 11.3% by radiotherapy, 6.6% by additional progesterone. (4) The survival period of the patients was related to pathologic types and clinical stages and ages of the patients.
  • CONCLUSIONS: The clinical symptom of uterine sarcoma is nonspecific (mostly abnormal vaginal bleeding) and the prognosis is poor.
  • The patients with leiomyosarcoma are younger and have better prognosis, but the rate of preoperative diagnosis is low.
  • The prognosis of uterine sarcoma is related to pathologic types, clinical stage and ages of the patients.
  • [MeSH-major] Sarcoma / pathology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783345.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Lee JW, Kim YT, Min YH, Kim JW, Kim SH, Park KH, Lim BJ, Yang WI: Granulocytic sarcoma of the uterine cervix. Int J Gynecol Cancer; 2004 May-Jun;14(3):553-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the uterine cervix.
  • Granulocytic sarcoma (GS) is a rare manifestation of leukemia and has been reported in 3-5% of acute myelogenous leukemia (AML) patients.
  • However, she visited the hospital because of painless vaginal bleeding.
  • Systemic chemotherapy was administered on the presumption that myelogenous leukemia had recurred as chloroma, and a good clinical response was achieved.
  • We describe the first case of AML that relapsed as chloroma of the uterine cervix after complete remission of the AML, which had complete response to only systemic chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute. Sarcoma, Myeloid / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Diagnosis, Differential. Female. Humans


11. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, Tinar S: Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1239-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases.
  • Tamoxifen (TAM) is widely used in the treatment of breast cancer, and its paradoxical effects on female genital system are well known.
  • Four uterine sarcoma patients who had history of TAM usage for previous breast cancer are presented in this study.
  • The mean time of exposure to TAM was 6 (range 3-11) years, and the mean cumulative dose of drug was 43.82 g.
  • All patients were postmenopausal, and the mean age was 66 (range 61-73) years at the time of the diagnosis of the uterine malignancy.
  • In one (25%) patient was diagnosed with endometrial biopsy made for a postmenopausal vaginal bleeding; the others (75%) were asymptomatic and their diseases were diagnosed during the pelvic examination and transvaginal ultrasonography.
  • All patients underwent surgery +/- adjuvant therapy (chemotherapy and/or radiation therapy), and two (50%) patients died because of the sarcoma.
  • In consequence, early detection of TAM-related uterine sarcoma is required for orderly gynecological examination in patients having history of TAM usage for previous breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Leiomyosarcoma / chemically induced. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / therapy. Combined Modality Therapy. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans. Mastectomy. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343223.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


12. Goker BO, Bese T, Ilvan S, Yilmaz E, Demirkiran F: A case with multiple gynecological malignancies. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):372-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with cervical non-Hodgkin lymphoma was treated with chemotherapy.
  • Fourteen months after the diagnosis of the lymphoma, an endometrial adenocarcinoma was detected as a secondary malignant tumor.
  • Approximately 7 years after the diagnosis of endometrial cancer, vaginal invasive squamous cell carcinoma was diagnosed as the third primary malignancy, and a second-line palliative radiotherapy was applied.
  • Seven months after the last radiotherapy, postradiational sarcoma in the vagina was diagnosed.
  • Congenital and acquired immune system disorders, viral oncogenes, and various human leukocyte antigen (HLA) types were investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Uterine Cervical Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823128.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK: [Clinical review of 97 patients with endometrial stromal sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):115-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of 97 patients with endometrial stromal sarcoma].
  • OBJECTIVE: To review the survival outcomes in patients with endometrial stromal sarcoma (ESS) in Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, and to discuss prognostic factors and the role of post-operative adjuvant radiotherapy and chemotherapy.
  • The median age at diagnosis was 44.0 years.
  • The median follow-up time was 62 months (5 - 277 months).
  • Atypical vaginal bleeding (43%) and prolonged and increased menses (36%) were the main symptoms.
  • The median time-to-recurrence (TTR) was 27 months.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / pathology. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovariectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683750.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS: Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases.
  • The aim of this retrospective study was to evaluate the clinical behavior and management outcome of low-grade endometrial stromal sarcoma (LGESS).
  • The most common presenting symptom was abnormal vaginal bleeding.
  • Six patients had adjuvant therapy after the hysterectomy.
  • Recurrent disease was treated with surgery (one case), surgery plus chemotherapy (five cases), chemotherapy (two cases), and surgery plus radiotherapy (two cases).
  • Treatment with a bilateral salpingo-oophorectomy or adjuvant chemoradiation did not affect the disease-free interval.
  • Surgery is the primary treatment for recurrent endometrial stromal sarcoma when feasible.
  • Adjuvant treatment (radiotherapy, chemotherapy, or both) had no effect on the prognosis of patients with stage I disease.
  • [MeSH-major] Sarcoma, Endometrial Stromal / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179547.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kilic G, Boruban MC, Bueco-Ramos C, Konoplev SN: Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy. Eur J Gynaecol Oncol; 2007;28(4):270-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy.
  • Granulocytic sarcoma is an extramedullary tumor associated with acute myelogenous leukemia (AML) and it is rarely seen in the female genital tract.
  • We report an unusual case of granulocytic sarcoma of the uterus and fallopian tube in an AML patient who presented with vaginal bleeding and persistent abdominal pain.
  • She was under chemotherapy.
  • Biopsy did not reveal the diagnosis.
  • Pathology showed atypical myeloid cells infiltrating the muscle bundles which was consistent with granulocytic sarcoma involving the uterus and right fallopian tube.
  • Immunohistochemistry confirmed the diagnosis.
  • The patient is in complete remission for AML and being followed-up for granulocytic sarcoma.
  • Granulocytic sarcoma of the uterus and fallopian tube is very rare, and in AML patients with abnormal uterine bleeding but negative endometrial biopsy it should still be considered in the differential diagnosis.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713090.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Hensley ML: Uterine/female genital sarcomas. Curr Treat Options Oncol; 2000 Jun;1(2):161-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Choosing the best management of uterine and vulvo-vaginal sarcomas depends on careful histologic review of the pathologic specimen.
  • Prognosis and treatment vary greatly depending on specific histology, grade, and tumor stage.
  • The initial approach to sarcomas of the female genital tract, with the occasional exception of vulvo-vaginal rhabdomyosarcoma, is surgery.
  • It is frequently used as adjuvant therapy for resected high-grade or margin-positive vulvo-vaginal sarcomas, and for endometrial stromal sarcomas.
  • Adjuvant chemotherapy has not been demonstrated to improve survival in vulvo-vaginal sarcomas, with the exception of vulvo-vaginal rhabdomyosarcomas, nor has it been demonstrated to improve survival in uterine sarcomas.
  • Chemotherapy may be used for recurrent or persistent disease.
  • The choice of agent depends on the histologic type of sarcoma.
  • [MeSH-major] Sarcoma / therapy. Uterine Neoplasms / therapy. Vaginal Neoplasms / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Obstet Gynecol. 1979 Jul 1;134(5):557-64 [453295.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Obstet Gynecol. 1985 May;65(5):699-704 [2984620.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):311-6 [6197155.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2487-92 [2684386.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Obstet Gynecol. 1989 Jan;73(1):75-8 [2462203.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2003-7 [3756818.001]
  • [Cites] Obstet Gynecol. 1984 Apr;63(4):550-6 [6322081.001]
  • [Cites] Am J Obstet Gynecol. 1990 Apr;162(4):968-74; discussion 974-6 [2327466.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1264-7 [3815302.001]
  • [Cites] Am J Obstet Gynecol. 1987 Mar;156(3):660-2 [3826216.001]
  • [Cites] Radiother Oncol. 1990 Feb;17(2):123-32 [2157241.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1847-53 [2230871.001]
  • [Cites] Obstet Gynecol. 1984 Aug;64(2):173-8 [6738952.001]
  • [Cites] Gynecol Oncol. 1985 Mar;20(3):281-9 [3838290.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3333-55 [10506637.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):389-95 [10366465.001]
  • [Cites] Obstet Gynecol. 1973 Oct;42(4):522-6 [4742656.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Obstet Gynecol. 1986 Nov;68(5):709-14 [3763088.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1736-44 [10561210.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50 [2453004.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Obstet Gynecol. 1979 Feb;53(2):213-7 [418977.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • (PMID = 12057054.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


17. Eltabbakh GH, Shamonki MI, Moody JM, Garafano LL: Hysterectomy for obese women with endometrial cancer: laparoscopy or laparotomy? Gynecol Oncol; 2000 Sep;78(3 Pt 1):329-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hysterectomy for obese women with endometrial cancer: laparoscopy or laparotomy?
  • OBJECTIVE: The aim of this study was to investigate the feasibility and safety of laparoscopic management of obese women with early stage endometrial cancer and to compare the surgical outcome, cost, hospital stay, recall of postoperative pain control, time to return to full activity and to work, and overall satisfaction among these women and those managed by laparotomy.
  • METHODS: We conducted a prospective study over 2 years applying laparoscopic surgery to all women with clinical stage I endometrial cancer and body mass indices (BMIs) between 28.0 and 60.0 who can tolerate such surgery.
  • As a control, we used women with clinical stage I endometrial cancer and similar BMIs who underwent laparotomy in the previous 2 years.
  • Both groups were compared in their characteristics, surgical outcome, cost, and hospital stay, and interviewed regarding time to recovery, recall of postoperative pain control, and overall satisfaction with their management.
  • RESULTS: Forty of 42 obese women who presented with clinical stage I endometrial cancer during the study period were offered laparoscopic surgery.
  • The procedure was converted to laparotomy in 3 (7.5%) patients.
  • Women who underwent laparoscopy had a significantly longer operative time, more pelvic lymph nodes removed, a smaller drop in postoperative hematocrit, less pain medication, and a shorter hospital stay (194.8 versus 137.7 min, P <0.001; 11.3 versus 5.3, P < 0.001; 3.9 versus 5.4, P = 0.029; 32.3 versus 124.1 mg, P < 0.001; and 2.5 versus 5.6 days, P < 0.001, respectively).
  • CONCLUSIONS: Most obese women with early stage endometrial cancer can be safely managed through laparoscopy with excellent surgical outcome, shorter hospitalization, and less postoperative pain than those managed through laparotomy.
  • [MeSH-major] Endometrial Neoplasms / surgery. Hysterectomy, Vaginal / methods. Obesity / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Transfusion. Feasibility Studies. Female. Hematocrit. Humans. Intraoperative Care. Laparoscopy / adverse effects. Laparoscopy / economics. Laparoscopy / methods. Laparotomy / adverse effects. Laparotomy / economics. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pain, Postoperative / drug therapy. Pain, Postoperative / etiology. Prospective Studies. Sarcoma / pathology. Sarcoma / surgery. Treatment Outcome. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10985889.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Farley J, O'Boyle JD, Heaton J, Remmenga S: Extraosseous Ewing sarcoma of the vagina. Obstet Gynecol; 2000 Nov;96(5 Pt 2):832-4
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous Ewing sarcoma of the vagina.
  • BACKGROUND: Ewing sarcoma is a highly malignant childhood bone neoplasm.
  • Extraosseous presentations of Ewing sarcomas include the trunk, extremities, uterus, cervix, and vagina.
  • CASE: A 35-year-old woman, gravida 3, para 3, presented with a painless vaginal mass.
  • After surgical excision, pathology results diagnosed an extraosseous Ewing sarcoma.
  • Chemotherapy was given, followed by external beam and vaginal intracavitary brachytherapy, then more chemotherapy.
  • After 48 months post-treatment, there is no clinical evidence of recurrence.
  • CONCLUSION: Although rare, Ewing sarcoma can present as a vaginal mass.
  • [MeSH-major] Sarcoma, Ewing / pathology. Vaginal Neoplasms / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094227.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Nag S, Tippin D, Ruymann FB: Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas. J Pediatr Hematol Oncol; 2003 Jun;25(6):448-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas.
  • BACKGROUND: The purpose of this study was to determine the long-term local control, disease-free survival, and morbidity of fractionated high-dose-rate brachytherapy (F-HDR) in infants and children with soft tissue sarcomas.
  • PATIENTS AND METHODS: Fifteen children (13 girls and 2 boys, ages 5-101 months) with soft tissue sarcomas were treated with chemotherapy, organ-preserving surgery, and F-HDR (36 Gy in 12 fractions) to post-chemotherapy volumes.
  • External beam radiotherapy was not part of the primary treatment, although four patients (27%) subsequently received salvage external beam radiotherapy after treatment failure.
  • Chemotherapy was administered to all patients based on their tumor histology and stage.
  • With longer follow-up, grade 3 to 4 brachytherapy-related late morbidities increased from 8% (1/12) to 20% (3/15) and included trismus/osteonecrosis, vaginal stenosis, and periurethral fibrosis.
  • There were two late complications associated with puberty that occurred 8 to 10 years after the initial treatments.
  • CONCLUSIONS: As the sole radiation modality, F-HDR achieved excellent local control and disease-free survival in properly selected children with soft tissue sarcomas while preserving normal bone and organ development.
  • A significant percentage of patients experience adverse late sequelae as a result of this treatment.
  • [MeSH-major] Brachytherapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Infant. Male. Morbidity. Neoplasm Recurrence, Local. Organ Preservation. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / radiotherapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12794522.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N: [Malignant tumors of the uterus]. Ther Umsch; 2007 Jul;64(7):381-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Maligne Tumoren des Uterus.
  • Malignant uterine tumors are responsible for up to 9% of all new cancer cases and for 4.5% of all cancer related deaths in women.
  • Endometrial cancers are typically found in elderly women and are > 70% hormone sensitive (type I), type II is often less differentiated and not hormone sensitive.
  • Diagnosis can be achieved by vaginal ultrasound and by histology after hysteroscopy and curettage of the uterine cavity.
  • Therapy of choice is the stage related radical hysterectomy (incl. lymphnode dissection).
  • Postoperatively and at progressive stages endocrine and radiation therapies can be useful.
  • Chemotherapy is only useful in not hormone sensitive and in progressive tumors.
  • These often aggressive tumors are hardly responding to systemic and radiation therapy.
  • Therefore radical tumor surgery plays the main therapeutic role.
  • [MeSH-major] Sarcoma. Uterine Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cervix Uteri / pathology. Combined Modality Therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Endometrium / pathology. Female. Humans. Hysterectomy. Hysteroscopy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Postoperative Care. Risk Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948755.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


21. Gupta D, Deavers MT, Silva EG, Malpica A: Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol; 2004 Jun;28(6):771-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian malignant melanoma (MM), primary or metastatic, is an extremely rare tumor and in the absence of a previous diagnosis can represent a diagnostic challenge.
  • The tumor cell type was epithelioid in 19 cases, spindled in 2 cases, mixed epithelioid and spindled in 1 case, and small cell in 1 case.
  • In 8 cases, initial diagnoses included sex cord stromal tumor, germ cell tumor, sarcoma, or undifferentiated carcinoma.
  • Treatment performed in 18 of the cases are as follows: oophorectomy with/without chemotherapy (10); total abdominal hysterectomy with bilateral salpingo-oophorectomy with/without chemotherapy (6); vaginal hysterectomy, bilateral salpingo-oophorectomy, and chemotherapy (1); and total abdominal hysterectomy with salpingo-oophorectomy (1).
  • Nodular or diffuse pattern and epithelioid cell type are most frequently seen, and the tumor can be mistaken for germ cell and sex cord stromal tumors.
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Calbindin 2. DNA-Binding Proteins / analysis. Ethnic Groups. Female. Humans. Hysterectomy. Immunohistochemistry. Inhibins / analysis. MART-1 Antigen. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor. Middle Aged. Monophenol Monooxygenase / analysis. Neoplasm Metastasis. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. S100 Proteins / analysis. Teratoma / pathology. Transcription Factors / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15166669.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA-Binding Proteins; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Transcription Factors; 57285-09-3 / Inhibins; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


22. Akçay MN: Metastatic disease in the breast. Breast; 2002 Dec;11(6):526-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is the commonest malignancy in women.
  • Metastatic disease of the breast is therefore often an unexpected diagnosis in a female patient presenting with a breast mass.
  • Of solid tumors at other sites, the most common cancers to metastasize to the breast are, in declining order of frequency, malignant melanoma, lymphoma, lung cancer, ovarian carcinoma, soft tissue sarcoma, and gastrointestinal and genitourinary tumors.
  • Besides these, metastases from osteosarcoma, thyroid neoplasms, and cervical, vaginal and endometrial carcinomas to the breast have been sporadically reported in the literature.
  • Lesions that metastasize to the breast may produce changes that look similar to those of primary breast cancer on mammography, but they are more likely to be multiple, are frequently bilateral, and form a nidus of tumor cells that are usually round with fairly well-defined margins.
  • Diagnosis is generally achieved by means of fine-needle aspiration cytology or open biopsy of the breast masses.
  • In recent reports, particular importance has been attached to the performance of fine-needle aspiration cytology diagnosis, to differentiate a metastasis from a second primary tumor, thus making it possible to avoid unnecessary mastectomy and ensure that appropriate chemotherapy and radiotherapy are implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


23. Núñez M, Soriano V: [Cancer and human immunodeficiency virus in the era of combination therapy]. Med Clin (Barc); 2000 Jun 17;115(3):93-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer and human immunodeficiency virus in the era of combination therapy].
  • [Transliterated title] Cáncer y virus de la inmunodeficiencia humana en la era de la terapia combinada.
  • [MeSH-minor] Condylomata Acuminata / complications. Drug Therapy, Combination. Female. Female Urogenital Diseases / etiology. Humans. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Male. Male Urogenital Diseases. Papillomaviridae. Papillomavirus Infections / complications. Prisoners. Risk Factors. Sarcoma, Kaposi / etiology. Tumor Virus Infections / complications. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / etiology. Uterine Cervical Neoplasms / virology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965483.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Editorial
  • [Publication-country] SPAIN
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down






Advertisement